Veröffentlichungsdatum: 16 Juni 2004
Projektträger – zwischengeschaltetes Finanzinstitut
Fresenius – The Health Care Group.Ort
Beschreibung
The project concerns the promoter’s Research and Development expenditures in medical care and biotechnology (antibodies and cell therapy) and upgrading of existing manufacturing facilities for dialysis and products.
Ziele
The research activities aim at the innovation of high-quality products and new therapy approaches in line with the Bank’s Innovation 2010 Initiative. The promoter’s main production facilities in dialysis technology are located in Objective 2 areas for allocations from the EU Structural Fund. The project will result in creation of some new jobs while safeguarding existing employment.
Kommentar(e)
Fabrication of medical equipment and pharmaceuticals.
Sektor(en)
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 232m.
Gesamtkosten (voraussichtlicher Betrag)
Up to EUR 330m.
Umweltaspekte
Compliance with EU environmental directives and national laws shall be ensured.
Auftragsvergabe
Procurement regulations do not apply to this private industry project. The promoter carries out competitive enquiries among potential suppliers for goods and services, as is usual in the industry.
Projektstatus
Unterzeichnet - 13/07/2005